In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Robbie Tyrie, founder and managing director of Torridon ...

From patient engagement apps to clinical trial management platforms, development teams are increasingly turning to AI coding ...

Roche has added to its weight-loss drug pipeline again, turning to China's Rona Therapeutics for an RNAi candidate targeting ...

Women and girls with autoimmune diseases are much more likely to have their condition misdiagnosed as psychiatric or ...

Aspen Neuroscience, which is developing stem cell therapies for Parkinson's disease, has filed an IPO to raise additional ...

Saunders' latest spell as CEO started in 2023, as Bausch Health worked to spin Bausch + Lomb out as an independent public ...

Operational review meeting minutes released by the Department of Health and Social Care (DHSC) reveal that the industry and ...

Bristol Myers Squibb has reported phase 3 results with a new type of drug for idiopathic pulmonary fibrosis (IPF) that could ...

Just over a year has passed since the Trump administration sent letters to 17 leading manufacturers demanding steps towards ...

Asahi Kasei's $920 million takeover of German biotech Aicuris in April has paid off with FDA approval for the herpes simplex ...

Expectations for Wnt pathway-targeting trispecific antibody remigromig (MK-3000, formerly known as EYE103) were riding high ...

AstraZeneca has already filed for approval of its therapy for ultra-rare disease hypophosphatasia (HPP), after missing the ...